カテゴリ： GlobalData, アメリカ, 企業調査

BioMarin Pharmaceutical Inc (BMRN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：BioMarin Pharmaceutical Inc (BMRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9874
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：107
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions, such as Kyndrisa (drisapersen), Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. Its product category consists of multiple clinical and preclinical offerings. The company operates through its manufacturing facilities in Novato, California. It conducts its buisiness operations in the US, Europe, Latin America, the Middle East, and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

BioMarin Pharmaceutical Inc (BMRN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
BioMarin Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 12
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
ProSensa Raises US$30 Million In Series C Financing Round 15
Partnerships 17
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 17
Licensing Agreements 18
Avrobio Enters into Licensing Agreement with BioMarin Pharma 18
Sarepta Therapeutics Enters into Licensing Agreement with BioMarin Pharma 19
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 21
BioMarin Enters Into Licensing Agreement With Repligen For Histone Deacetylase Inhibitor Portfolio 22
Shire Human Genetic Enters into Licensing Agreement with Biomarin Pharma 23
Catalyst Pharma Amends Licensing Agreement with BioMarin Pharmaceutical 24
BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children’s Research Hospital For Hemophilia A Gene Therapy Program 26
Equity Offering 28
BioMarin Pharma Raises USD720 Million in Public Offering of Shares 28
BioMarin Pharma Raises USD911.5 Million in Public Offering of Shares 29
BioMarin Pharma Completes Public Offering Of Shares For US$119.3 Million 30
BioMarin Completes Public Offering Of Common Stock For US$236 Million 31
Debt Offering 32
BioMarin Pharma Completes Underwriters Exercise of Over-Allotment Option of 0.599% Notes Due 2024 for USD45 Million 32
BioMarin Pharma Completes Public Offering Of Notes Due 2020 For US$375 Million 33
BioMarin Pharma Completes Public Offering Of Notes Due 2018 For US$375 Million 35
Asset Transactions 37
Medivation Acquires Rights to Talazoparib from BioMarin Pharma 37
Acquisition 38
Sanofi May Acquire BioMarin Pharma 38
Roche May Acquire BioMarin Pharma 39
BioMarin Pharmaceutical (BioMarin Pharma) Acquires 100% stake in Prosensa for USD751.5 Million 40
Roche Rumored to Acquire BioMarin Pharma for USD13.5 Billion 42
BioMarin Pharma Acquires Zacharon Pharma For USD9.7 Million 43
GlaxoSmithKline Plans To Acquire BioMarin Pharma 44
BioMarin Pharmaceutical Inc – Key Competitors 45
BioMarin Pharmaceutical Inc – Key Employees 46
BioMarin Pharmaceutical Inc – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Joint Venture 48
Recent Developments 49
Financial Announcements 49
Oct 25, 2018: BioMarin Pharmaceutical reports third quarter 2018 results 49
Aug 02, 2018: BioMarin announces second quarter 2018 results 52
Apr 25, 2018: BioMarin Announces First Quarter 2018 Financial Results 55
Feb 22, 2018: BioMarin Reports Fourth Quarter 2017 Financial Results 58
Oct 26, 2017: BioMarin Announces Third Quarter 2017 Financial Results 61
Aug 02, 2017: BioMarin Announces Second Quarter 2017 Financial Results 65
May 04, 2017: BioMarin Announces First Quarter 2017 Financial Results 67
Feb 23, 2017: BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results 69
Jan 10, 2017: BioMarin Transfers Duchenne Natural History Database to CureDuchenne To Improve Knowledge of Duchenne Patients and Improve Clinical Outcomes 71
Corporate Communications 72
Oct 03, 2017: BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors 72
Product News 73
Dec 14, 2017: Gene therapy success could lead to cure for haemophilia 73
12/11/2017: BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting 74
12/06/2017: BioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & Exposition 76
09/06/2017: BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome at 13th International Congress of Inborn Errors of Metabolism 2017 77
09/05/2017: BioMarin To Present Data On ICV BMN 250 At 13th International Congress of Inborn Errors of Metabolism 2017 79
07/11/2017: BioMarins Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels within Normal Range for over One Year 81
06/16/2017: BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 Congress 83
05/22/2018: BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress 84
05/17/2018: BioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress 86
05/15/2018: BioMarin Announces First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy in Severe Hemophilia A Patients with Pre-existing AAV5 Antibodies 88
04/27/2017: FDA approves first treatment for a form of Batten disease 89
04/21/2017: New medicine for rare neurodegenerative disorder in children 91
04/21/2017: BioMarin Receives Positive CHMP Opinion in Europe for Brineura (cerliponase alfa) for First Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare and Fatal Brain Disorder in Children 92
03/21/2018: BioMarin’s Gene Therapy Manufacturing Facility Recognized with Industry Award 94
02/07/2018: BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at WORLDSymposium 2018 95
01/08/2017: BioMarin to Provide Update to Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A at 35th Annual J.P. Morgan Healthcare Conference 97
Product Approvals 99
Feb 01, 2017: BioMarin Receives Access to Priority Medicines Regulatory Support from EMA for BMN 270 Gene Therapy in Hemophilia A 99
Clinical Trials 100
Jan 23, 2018: Local researcher leads breakthrough for haemophilia patients 100
Dec 19, 2017: BioMarin Doses First Patient in Global GENEr8-1 Phase 3 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A 101
Dec 09, 2017: BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology Annual Meeting Concurrent with NEJM Publication 102
Oct 26, 2017: FDA Grants Breakthrough Therapy Designation for BioMarin’s Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A 104
Aug 02, 2017: BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies 105
Appendix 107
Methodology 107
About GlobalData 107
Contact Us 107
Disclaimer 107

List of Tables
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioMarin Pharmaceutical Inc, Deals By Therapy Area, 2012 to YTD 2018 10
BioMarin Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 12
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
ProSensa Raises US$30 Million In Series C Financing Round 15
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 17
Avrobio Enters into Licensing Agreement with BioMarin Pharma 18
Sarepta Therapeutics Enters into Licensing Agreement with BioMarin Pharma 19
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 21
BioMarin Enters Into Licensing Agreement With Repligen For Histone Deacetylase Inhibitor Portfolio 22
Shire Human Genetic Enters into Licensing Agreement with Biomarin Pharma 23
Catalyst Pharma Amends Licensing Agreement with BioMarin Pharmaceutical 24
BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children's Research Hospital For Hemophilia A Gene Therapy Program 26
BioMarin Pharma Raises USD720 Million in Public Offering of Shares 28
BioMarin Pharma Raises USD911.5 Million in Public Offering of Shares 29
BioMarin Pharma Completes Public Offering Of Shares For US$119.3 Million 30
BioMarin Completes Public Offering Of Common Stock For US$236 Million 31
BioMarin Pharma Completes Underwriters Exercise of Over-Allotment Option of 0.599% Notes Due 2024 for USD45 Million 32
BioMarin Pharma Completes Public Offering Of Notes Due 2020 For US$375 Million 33
BioMarin Pharma Completes Public Offering Of Notes Due 2018 For US$375 Million 35
Medivation Acquires Rights to Talazoparib from BioMarin Pharma 37
Sanofi May Acquire BioMarin Pharma 38
Roche May Acquire BioMarin Pharma 39
BioMarin Pharmaceutical (BioMarin Pharma) Acquires 100% stake in Prosensa for USD751.5 Million 40
Roche Rumored to Acquire BioMarin Pharma for USD13.5 Billion 42
BioMarin Pharma Acquires Zacharon Pharma For USD9.7 Million 43
GlaxoSmithKline Plans To Acquire BioMarin Pharma 44
BioMarin Pharmaceutical Inc, Key Competitors 45
BioMarin Pharmaceutical Inc, Key Employees 46
BioMarin Pharmaceutical Inc, Subsidiaries 47
BioMarin Pharmaceutical Inc, Joint Venture 48

List of Figures
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
BioMarin Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[BioMarin Pharmaceutical Inc (BMRN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Wns (Holdings) Limited
    Wns (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Wns (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • ElectraNet Pty Ltd：企業の戦略的SWOT分析
    ElectraNet Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Gammon Construction Ltd：企業の戦略的SWOT分析
    Gammon Construction Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • National Power Corp：企業の戦略的SWOT分析
    National Power Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Equinix Inc (EQIX)：企業の財務・戦略的SWOT分析
    Equinix Inc (EQIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Yanlord Land Group Ltd：戦略・SWOT・企業財務分析
    Yanlord Land Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Yanlord Land Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • OSRAM Opto Semiconductors GmbH：企業の戦略的SWOT分析
    OSRAM Opto Semiconductors GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Alarko Holding AS (ALARK)：企業の財務・戦略的SWOT分析
    Alarko Holding AS (ALARK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Aeroports de Paris SA：戦略・SWOT・企業財務分析
    Aeroports de Paris SA - Strategy, SWOT and Corporate Finance Report Summary Aeroports de Paris SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Misonix Inc (MSON)：企業の財務・戦略的SWOT分析
    Misonix Inc (MSON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Immunomedics Inc (IMMU)：企業の財務・戦略的SWOT分析
    Immunomedics Inc (IMMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • FOX Broadcasting Co：企業の戦略的SWOT分析
    FOX Broadcasting Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • TAS S.p.A. (TAS)：企業の財務・戦略的SWOT分析
    TAS S.p.A. (TAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Legal & General Group Plc：企業のM&A・事業提携・投資動向
    Legal & General Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Legal & General Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Aduro BioTech Inc (ADRO)：製薬・医療：M&Aディール及び事業提携情報
    Summary Aduro BioTech Inc (Aduro BioTech) is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sti …
  • Eureka Forbes Limited：企業の戦略的SWOT分析
    Eureka Forbes Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • ITT Inc.：企業の戦略・SWOT・財務情報
    ITT Inc. - Strategy, SWOT and Corporate Finance Report Summary ITT Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Nikkei Inc.：企業の戦略的SWOT分析
    Nikkei Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • KeyCorp：企業の戦略・SWOT・財務情報
    KeyCorp - Strategy, SWOT and Corporate Finance Report Summary KeyCorp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Deutsche Wohnen AG：企業のM&A・事業提携・投資動向
    Deutsche Wohnen AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Deutsche Wohnen AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆